tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market
Holding ALLO?
Track your performance easily

Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

1,310 Followers

Allogene Therapeutics (ALLO) Ownership Overview

10.23%29.02%27.66%10.64%22.46%
10.23% Insiders
27.66% Other Institutional Investors
10.64% ETFs
22.46% Public Companies and Individual Investors
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 67.31% of the company’s stock is owned by Institutional Investors, 10.23% is owned by Insiders, and 22.46% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 03, 2024
Franz Humer
Director
xxxxxxxxxxxxx
$26096
May 20, 2024
xxxxxxxxxxxxx
$4999997
Mar 06, 2024
xxxxxxxxxxxxx
$682

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$677885
Sep 30, 2024
xxxxxxxxxxxxx
$12220040
Sep 30, 2024
xxxxxxxxxxxxx
$15871128

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,099,279Insider4.82%23,026,356
7,931,219Institution3.78%18,083,179
7,723,302Insider3.68%17,609,129
7,035,377Institution3.36%16,040,660
6,896,552Institution3.29%15,724,139
6,880,475Institution3.28%15,687,483
6,295,286Institution3.00%14,353,252
5,772,200Institution2.75%13,160,616
5,668,260Institution2.70%12,923,633
5,039,432Institution2.40%11,489,905

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,035,377Institution3.36%16,040,660
6,896,552Institution3.29%15,724,139
6,880,475Institution3.28%15,687,483
5,772,200Institution2.75%13,160,616
5,039,432Institution2.40%11,489,905
4,604,376Institution2.20%10,497,977
4,271,720Institution2.04%9,739,522
3,537,479Institution1.69%8,065,452
2,059,978Institution0.98%4,696,750
1,988,965Institution0.95%4,534,840

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,337,709Institution2.07%11,082,847
3,535,242Institution1.69%8,060,352
3,373,485Institution1.61%7,455,402
2,461,455Institution1.17%6,289,018
1,244,789Institution0.59%2,838,119
946,058Institution0.45%2,157,012
757,340Institution0.36%1,673,721
733,976Institution0.35%1,622,087
582,270Institution0.28%1,487,700
451,289Institution0.22%1,153,043

FAQ

Who Owns Allogene Therapeutics Inc (ALLO)?
According to the latest TipRanks data, approximately 27.66% of the company's stock is held by institutional investors, 10.23% is held by insiders, and 22.46% is held by retail investors.
    What percentage of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 27.66% of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors.
      What percentage of Allogene Therapeutics Inc (ALLO) stock is held by retail investors?
      According to the latest TipRanks data, approximately 22.46% of Allogene Therapeutics Inc (ALLO) stock is held by retail investors.
        Who owns the most shares of Allogene Therapeutics Inc (ALLO)?
        Arie Belldegrun owns the most shares of Allogene Therapeutics Inc (ALLO).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis